To study if the selectivity profile of eCF506 translate into weaker phenotypic activity against ABL-driven cancer cells relative to classical SRC/ABL inhibitors, we performed cell proliferation assays with three BCR-ABL-positive chronic myeloid leukemia (CML) cell lines: LAMA-84, KCL-22, and K-562. Here, SRC is linked to cancer.